Search Results for: US Rheumatoid Arthritis Treatment Market
Articles
GLOBAL REPORT - 2017 Global Drug Delivery & Formulation Report: Part 2, Notable Product Approvals of 2017 April 5, 2018
In part 2 of this 4-part series, PharmaCircle in collaboration with Drug Development & Delivery, reviews the more interesting individual products approved throughout the past year.
MONOCLONAL ANTIBODIES - The Development of Therapeutic Monoclonal Antibody Products: A Comprehensive Guide to CMC Activities From Clone to Clinic April 3, 2018
Howard L. Levine, PhD, and Brendan R. Cooney, provide a guide to product development companies, service providers, investors, and analyst as they work their way through the complex and rapidly evolving world of therapeutic monoclonal antibodies.
DEVICE TRAINING - Maximizing Patient Adherence by Minimizing the Forgetting Curve January 9, 2018
Chris Evans explains how it is important that pharmaceutical companies and their drug delivery system partners proactively address the forgetting curve by rethinking how patients learn to use self-administration systems.
NEXT-GENERATION SEQUENCING - Emerging Clinical Applications & Projections to 2022 November 20, 2017
Laurie L. Sullivan and John Bergin, MS, MBA, say the growth curve for clinical applications of NGS is approaching an upward trajectory as existing applications gain traction and new ones begin to establish a foothold.
SPECIAL FEATURE - Injectable Drug Delivery: New Technologies Deliver Biologics & Differentiate Brands September 12, 2017
Contributor Cindy H. Dubin reports on a segment of the drug delivery industry that will see its market revenue double in just 5 years in response to a growing need to deliver highly viscous, high-volume drugs.
PHARMACEUTICAL PACKAGING - How Advances in Pharmaceutical Packaging Are Better Meeting Patients' Needs September 11, 2017
Detlev Haack, PhD, and Martin Koeberle, PhD, says an industry-wide focus on the design of packaging that can protect user-friendly dosage forms, as well as improve patient compliance and fit into modern consumers’ lifestyles, has resulted in a wide range of primary and secondary packaging solutions.
Aclaris Therapeutics Acquires Confluence Life Sciences August 14, 2017
Aclaris Therapeutics Acquires Confluence Life Sciences Aclaris Therapeutics, Inc. recently announced it has acquired Confluence Life Sciences, Inc., a privately...Sanofi & Regeneron Announce Biologics License Application Resubmission is Accepted for Review May 4, 2017
Sanofi and Regeneron Pharmaceuticals, Inc. recently announced that the US FDA has accepted the resubmission of Biologics License Application for...TiGenix Receives Positive Feedback From the FDA on Global Phase III Trial Protocol March 17, 2017
TiGenix NV, an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platform of allogeneic stem...Tiziana Life Sciences Announces New Data With Foralumab, a Fully Human Anti-CD3 Antibody November 21, 2016
Tiziana Life Sciences plc, the clinical-stage biotechnology company developing targeted drugs for cancer and autoimmune diseases, recently announced new data...ADVANCED DELIVERY DEVICES - Sophisticated Connected Wearables: Boosting Biologics’ Compliance, Value & Patient Satisfaction October 3, 2016
Michael D. Hooven, MSME, says the new, most advanced wearable large-volume injectors available now for clinical trials and commercial application are designed to address the challenges of formulating biologics, delivery complexity, patient compliance, and cost.
SPECIAL FEATURE - Injectable Drug Delivery: Key Trends Define Device Design Now & in the Future August 31, 2016
Contributor Cindy H. Dubin spoke with some of the world’s leading device developers about their current injection technologies and how their devices are addressing the current trends and opportunities in the industry.
Vifor Pharma Licenses Rights to Commercialize ChemoCentryx’s Orally Administered Complement 5aR Inhibitor May 17, 2016
Vifor Pharma and ChemoCentryx, Inc. recently announced that Vifor Pharma has licensed rights to commercialize CCX168, a Complement 5a Receptor...CEL-SCI Reports Record Monthly Patient Enrollment for Phase III Head & Neck Cancer Trial May 9, 2016
CEL-SCI Corporation recently announced that during the month of April, it has enrolled 41 patients in its ongoing Phase III...SPECIAL FEATURE - Prefilled Syringes & Parenteral Contract Manufacturing: Biologics Present a New Set of Challenges May 2, 2016
Contributor Cindy H. Dubin speaks with leading syringe developers and contract manufacturers to discuss how they are overcoming industry challenges and provides a look at some of the innovative advancements in prefilled syringe technology.
Novozymes Half-Life Extension Technology Embraced by Paras Biopharmaceuticals to Develop New Biobetter November 30, 2015
Novozymes Biopharma and Paras Biopharmaceuticals will collaborate to generate an improved version (a biobetter) of Teriparatide, a leading treatment for...MICRONEEDLE TECHNOLOGY - The New Potential of Microneedles for Biologics & Small Molecules November 18, 2015
Lisa A. Dick, PhD, describes how microneedle technology is being applied in two new transdermal systems using solid and hollow microneedles, which have the ability to deliver small molecules as well as biologics, opening up the potential for self-administration of a broad array of APIs
Ergomed Significantly Increases Contribution in CEL-SCI’s Phase III Trial October 8, 2015
CEL-SCI Corporation and its Clinical Research Organization (CRO) Ergomed plc recently announced they have expanded their co-development agreement with increased...Baxalta & Momenta Announce Initiation of Pivotal Clinical Trial for Biosimilar October 8, 2015
Baxalta Incorporated and Momenta Pharmaceuticals, Inc. recently announced the initiation of a pivotal clinical trial in patients with chronic plaque...Glenmark Pharmaceuticals' Novel Monoclonal Antibody to Enter Phase II September 8, 2015
Glenmark Pharmaceuticals S.A. recently announced that GBR 830, a novel monoclonal antibody has completed clinical Phase I dosing. GBR 830...
